Michael Mølhøj, Ph.D.

Vice President CMC

Michael Mølhøj joined Immatics in August 2020 and heads the Department of CMC Biologics responsible for all CMC aspects related to the pipeline of bispecific T cell receptor engaging molecules (TCER®). Michael brings 17+ years of Biotech/Pharma R&D experience (GLP/GMP) from driving scientific innovative efforts, leading process development and analytical activities, and developing advanced biotherapeutics towards IND/IMPD submission and clinical testing. Before joining Immatics, he worked for Hoffmann-La Roche (Penzberg, Germany) as technical project leader of T cell activating bispecific antibodies, and as mass spectrometry lab head and matrix lead. Prior to Roche, Michael worked for Micromet (now Amgen) and Scil Technology. He is a co-inventor of numerous patents and patent applications related to a range of therapeutic bispecific antibodies, bispecific antibody molecular formats, and analytical methods, and has co-authored multiple publications in international peer-reviewed journals. Michael holds a Master’s degree and a Ph.D. from the Faculty of Life Sciences at the University of Copenhagen, Denmark.